413 results on '"Allen C. Ho, MD"'
Search Results
2. Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor
3. Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor
4. Incidence and Risk Factors for Retinal Detachment and Retinal Tear after Cataract Surgery
5. Progression of Geographic Atrophy
6. Factors Associated with Fluctuations in Central Subfield Thickness in Patients with Diabetic Macular Edema Using Diabetic Retinopathy Clinical Research Protocols T and V
7. Restoration of Cone Sensitivity to Individuals with Congenital Photoreceptor Blindness within the Phase 1/2 Sepofarsen Trial
8. American Academy of Ophthalmology Intelligent Research in Sight (IRIS®) Registry and the IRIS Registry Analytic Center Consortium
9. MCO-010 optogenetic gene therapy for severe vision loss in Stargardt disease.
10. 8 Questions with Dr. Puliafito.
11. Cell Therapy Clinical Trials: An Update: Insight into the next generation of potential therapies entering our field of view.
12. Evaluating the Effect of Hypoglycemic Agents on Diabetic Retinopathy Progression.
13. Trends in Utilization of Vitreoretinal Services Following the Initial Phase of the 2020 COVID-19 Pandemic.
14. Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration.
15. Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa.
16. Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane (DEMO)
17. Inflammasomes in Cell Death in FTMH, ERM, and RRD
18. Research targets precision dosing for gene, cell therapy: Subretinal delivery provides direct surgical access, may be key to treating retinal diseases.
19. Reduction of Diabetic Macular Edema in the Untreated Fellow Eye Following Intravitreal Injection of Aflibercept.
20. The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy (CONTAIN)
21. Barriers to Follow-Up Retinal Care During the COVID-19 Pandemic: A Survey Study.
22. Comparative Incidence of Postoperative Hemorrhage in Vitreoretinal Surgery in Patients on Anti-Coagulants.
23. Administration of Ocular Gene Therapy.
24. REVERSIBLE RETINAL TOXICITY IN A PATIENT TAKING AXITINIB.
25. Research targets precision dosing for gene and cell therapy: Subretinal delivery provides direct surgical access to treat retinal diseases.
26. Characterizing Progression to Neovascular AMD in Fellow Eyes of Patients Treated With Intravitreal Anti-VEGF Injections.
27. TOPICAL DORZOLAMIDE–TIMOLOL WITH INTRAVITREOUS ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL VEIN OCCLUSION: A PILOT STUDY.
28. Endophthalmitis after cataract surgery: an update on recent advances.
29. Clinical Outcomes of Eyes With Diabetic Macular Edema Switched From Aflibercept to Ranibizumab Therapy.
30. Baseline Visual Acuity at Wet AMD Diagnosis Predicts Long-Term Vision Outcomes: An Analysis of the IRIS Registry.
31. Outcomes and Complications of In-Office Laser Demarcation of Peripheral Rhegmatogenous Retinal Detachments.
32. EN FACE VERSUS 12-LINE RADIAL OPTICAL COHERENCE TOMOGRAPHY SCAN PATTERNS FOR DETECTION OF MACULAR FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
33. Comparison of Residual Subfoveal Fluid by Intraoperative OCT After Macula-Involving RRD Repair Using Direct Drainage, Drainage Retinotomy, or Perfluoro-n-Octane.
34. Intravitreal Anti-Vascular Endothelial Growth Factor Injections for Macular Edema Associated With Central Retinal Vein Occlusion in Patients Age 40 Years or Younger.
35. Loss to Follow-Up in Patients With Retinal Vein Occlusion Undergoing Intravitreal Anti-VEGF Injections.
36. PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH POSTVIRAL PURTSCHER-LIKE RETINOPATHY.
37. NEWS AND COMMENT
38. Studies from Sidney Kimmel Medical College Add New Findings in the Area of Retinal Detachment (Incidence and Risk Factors for Retinal Detachment and Retinal Tear after Cataract Surgery).
39. En Face Optical Coherence Tomography of Bilateral Myopic Macular Retinoschisis.
40. Evaluation of the macula prior to cataract surgery.
41. MINIMAL ENDOILLUMINATION LEVELS AND DISPLAY LUMINOUS EMITTANCE DURING THREE-DIMENSIONAL HEADS-UP VITREORETINAL SURGERY.
42. The Potential Importance of Detection of Neovascular Age-Related Macular Degeneration When Visual Acuity Is Relatively Good.
43. Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial.
44. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF BRANCH RETINAL VEIN OCCLUSION.
45. Investigators start pivotal subretinal gene therapy trial.
46. Macular Hole Following Subretinal Tissue Plasminogen Activator for Submacular Hemorrhage Secondary to Neovascular AMD.
47. Why timing is everything in AMD: Surgeons' goal should be maintaining functional vision in more patients.
48. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
49. En Face Optical Coherence Tomography and Optical Coherence Tomography Angiography Imaging of Taxane-Associated Cystoid Macular Edema.
50. Effect of a Strict 'No-Talking' Policy During Intravitreal Injection on Post-Injection Endophthalmitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.